Non-invasive surrogate markers of pulmonary hypertension are associated with poor survival in patients with cancer

BackgroundCancer is one of the leading causes of death worldwide, and cardiopulmonary comorbidities may further adversely affect cancer prognosis. We recently described lung cancer-associated pulmonary hypertension (PH) as a new form of PH and comorbidity of lung cancer. While patients with lung can...

Full description

Saved in:
Bibliographic Details
Published in:BMJ open respiratory research 2024-08, Vol.11 (1), p.e001916
Main Authors: Cekay, Michael, Arndt, Philipp F, Franken, Johanna K, Wilhelm, Jochen, Pullamsetti, Soni Savai, Roller, Fritz C, Sommer, Natascha, Askevold, Ingolf, Lüdecke, Gerson, Langer, Christine, Stein, Marco, Zeppernick, Felix, Tello, Khodr, Sibelius, Ulf, Grimminger, Friedrich, Seeger, Werner, Savai, Rajkumar, Eul, Bastian
Format: Article
Language:English
Subjects:
Aged
Biomarkers - blood
Cancer therapies
Cardiovascular disease
Clinical outcomes
Coronary vessels
Emphysema
Female
Head & neck cancer
Humans
Hypertension, Pulmonary - mortality
Lung cancer
Lung Neoplasms - complications
Lung Neoplasms - mortality
Male
Medical diagnosis
Medical imaging
Medical prognosis
Metastasis
Middle Aged
Neoplasms - complications
Neoplasms - mortality
Nervous system
Patients
Prevalence
Primary Pulmonary Hypertension
Prognosis
Pulmonary arteries
Pulmonary Embolism
Pulmonary hypertension
Respiratory Measurement
Retrospective Studies
Software
Statistical analysis
Systemic disease and lungs
Tomography, X-Ray Computed
Tumors
Vein & artery diseases
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BackgroundCancer is one of the leading causes of death worldwide, and cardiopulmonary comorbidities may further adversely affect cancer prognosis. We recently described lung cancer-associated pulmonary hypertension (PH) as a new form of PH and comorbidity of lung cancer. While patients with lung cancer with PH had significantly reduced overall survival compared with patients without PH, the prevalence and impact of PH in other cancers remain unclear.MethodsIn this retrospective, observational cohort study, we analysed the prevalence and impact of PH on clinical outcomes in 1184 patients with solid tumours other than lung cancer, that is, colorectal, head and neck, urological, breast or central nervous system tumours, using surrogate markers for PH determined by CT.ResultsPH prevalence in this cohort was 10.98%. A Cox proportional hazard model revealed a significant reduction in the median survival time of patients with cancer with PH (837 vs 2074 days; p
ISSN:2052-4439
2052-4439
DOI:10.1136/bmjresp-2023-001916